Oligoastrocytoma

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:251656C71.9
Who is this for?
Show terms as
24Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Oligoastrocytoma, also known as mixed oligoastrocytoma or mixed glioma, is a rare brain tumor that historically was classified as containing both oligodendroglial and astrocytic tumor cell components. It falls under the broader category of diffuse gliomas and is classified under ICD-10 code C71.9 (malignant neoplasm of brain, unspecified). These tumors primarily affect the central nervous system, most commonly arising in the cerebral hemispheres, particularly the frontal and temporal lobes. Oligoastrocytomas were traditionally graded as either WHO grade II (low-grade) or WHO grade III (anaplastic oligoastrocytoma), with the anaplastic variant carrying a worse prognosis. Key symptoms depend on tumor location and size but commonly include seizures, headaches, cognitive changes, personality or behavioral alterations, focal neurological deficits such as weakness or speech difficulties, and increased intracranial pressure. Seizures are frequently the presenting symptom, particularly in lower-grade tumors. Some patients may experience nausea, vomiting, or visual disturbances as the tumor grows and exerts mass effect on surrounding brain structures. It is important to note that the 2016 and 2021 WHO Classifications of Tumors of the Central Nervous System have largely eliminated oligoastrocytoma as a distinct diagnostic entity. Advances in molecular diagnostics, particularly IDH mutation status and 1p/19q codeletion testing, now allow most previously diagnosed oligoastrocytomas to be reclassified as either oligodendrogliomas (IDH-mutant, 1p/19q-codeleted) or astrocytomas (IDH-mutant, non-codeleted). Treatment typically involves a combination of maximal safe surgical resection, radiation therapy, and chemotherapy (often with temozolomide or PCV regimen consisting of procarbazine, lomustine, and vincristine). Prognosis varies based on molecular profile, tumor grade, extent of resection, and patient age.

Also known as:

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

2 events
Apr 2024Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)

Ourotech, Inc.

TrialRECRUITING
Oct 2023Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

University of California, San Diego

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Oligoastrocytoma.

View clinical trials →

No actively recruiting trials found for Oligoastrocytoma at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Oligoastrocytoma community →

Specialists

24 foundView all specialists →
AM
Annick Desjardins, MD
DURHAM, NC
Specialist
PI on 7 active trials1 Oligoastrocytoma publication
JP
Jana Portnow
DUARTE, CA
Specialist
PI on 4 active trials
GM
Giles W. Robinson, MD
MEMPHIS, TN
Specialist
PI on 4 active trials1 Oligoastrocytoma publication
DG
David R Grosshans
HOUSTON, TX
Specialist
PI on 2 active trials
JM
John Boockvar, MD
BROOKLYN, NY
Specialist
PI on 10 active trials
KM
Katherine E Warren, M.D.
Specialist
PI on 7 active trials
DY
Debra N Yeboa
HOUSTON, TX
Specialist
PI on 1 active trial
PM
Patrick Wen, MD
BOSTON, MA
Specialist
PI on 6 active trials
TM
Tobey MacDonald
WASHINGTON, DC
Specialist
PI on 2 active trials5 Oligoastrocytoma publications
AM
Asha Das, MD
SAN DIEGO, CA
Specialist
PI on 4 active trials1 Oligoastrocytoma publication
JS
Juan Manuel Sepúlveda
Specialist
PI on 1 active trial5 Oligoastrocytoma publications
RP
Robert Prins
Specialist
PI on 1 active trial1 Oligoastrocytoma publication
DM
David A. Reardon, MD
Specialist
PI on 12 active trials
FM
Frank Lieberman, MD
PITTSBURGH, PA
Specialist
PI on 3 active trials
SM
Steven Kalkanis, MD
DETROIT, MI
Specialist
PI on 1 active trial
RF
Robert Fenstermaker
BUFFALO, NY
Specialist
PI on 2 active trials1 Oligoastrocytoma publication
PM
Patrick A. Thompson, MD
Specialist
PI on 2 active trials
JH
Jaymes Holland
Specialist
PI on 8 active trials15 Oligoastrocytoma publications
KM
Karen Gauvain, M.D.
Specialist
PI on 1 active trial
JM
Jennie Taylor, MD
Specialist
PI on 1 active trial
HP
Hideho Okada, MD, PhD
PITTSBURGH, PA
Specialist
PI on 2 active trials
TN
Timothy Cloughesy, MD, NO
LOS ANGELES, CA
Specialist
PI on 1 active trial1 Oligoastrocytoma publication
AM
Anna Vinitsky, MD, MS
MEMPHIS, TN
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Oligoastrocytoma.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OligoastrocytomaForum →

No community posts yet. Be the first to share your experience with Oligoastrocytoma.

Start the conversation →

Latest news about Oligoastrocytoma

Disease timeline:

New recruiting trial: Understanding Ozanimod's MOA Via Mass Cytometry in Ulcerative Colitis

A new clinical trial is recruiting patients for Oligoastrocytoma

New recruiting trial: Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)

A new clinical trial is recruiting patients for Oligoastrocytoma

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Oligoastrocytoma

What is Oligoastrocytoma?

Oligoastrocytoma, also known as mixed oligoastrocytoma or mixed glioma, is a rare brain tumor that historically was classified as containing both oligodendroglial and astrocytic tumor cell components. It falls under the broader category of diffuse gliomas and is classified under ICD-10 code C71.9 (malignant neoplasm of brain, unspecified). These tumors primarily affect the central nervous system, most commonly arising in the cerebral hemispheres, particularly the frontal and temporal lobes. Oligoastrocytomas were traditionally graded as either WHO grade II (low-grade) or WHO grade III (anaplas

How is Oligoastrocytoma inherited?

Oligoastrocytoma follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Oligoastrocytoma typically begin?

Typical onset of Oligoastrocytoma is adult. Age of onset can vary across affected individuals.

Which specialists treat Oligoastrocytoma?

24 specialists and care centers treating Oligoastrocytoma are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.